Source: Annual Congress 2001 - Novel approaches to treatment of lung disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Matuska, M. Bajer (Brno, Czech Republic). Cluster immunotherapy. SR theophylline in prevention of systemic reactions. Eur Respir J 2001; 16: Suppl. 31, 2897

Member's Comments

No comment yet.

Related content which might interest you: Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001 Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Desensitization therapy for allergic reactions of antituberculous drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006 Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003 Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002 Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019 Expression of inflammatory cytokines following stepwise dose reduction of corticosteroids of long-term oral corticosteroids users with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 62s Year: 2004 Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Bronchial asthma as neurogenic paroxysmal inflammatory disease - high efficacy of antiepileptic drug oxcarbazepine in asthma monotherapy Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005